Status:
COMPLETED
Foci of Tumor Heterogeneity in Diffuse Low-Grade Gliomas
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Glioma
Eligibility:
FEMALE
18-70 years
Brief Summary
Background: Diffuse low-grade gliomas (DLGG) are slow-growing primary-cancer of the brain and spinal cord. They represent up to 15% of the developing tumors in those organs with fatal outcome for the...
Detailed Description
IDH1-mutated gliomas are slow-growing brain tumors which progress into high-grade gliomas. The early molecular events causing this progression are ill-defined. Previous studies revealed that 20% of th...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- An individual must fulfill all of the following criteria in order to be eligible for study enrollment:
- Aged between 18 and 70 years.
- Suffering from IDH1-mutated diffuse low-grade glioma.
- No pre operative nor oncology treatment prior to join the study.
- Signed informed consent form.
- Exclusion criteria:
- Subject unable to read or/and write
- Grade 3 or 4 gliomas
- Tumor with IDH1-WT status
Exclusion
Key Trial Info
Start Date :
November 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2019
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04423094
Start Date
November 1 2016
End Date
March 30 2019
Last Update
June 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uh Montpellier
Montpellier, France, 34295